simvastatin has been researched along with Sclerosis, Systemic in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (28.57) | 29.6817 |
| 2010's | 5 (71.43) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kotyla, PJ | 1 |
| da Rocha Pitta, I; da Rocha Pitta, MG; Dantas, AT; de Almeida, AR; Duarte, ALBP; Gonçalves, RSG; Pereira, MC; Rego, MJBM | 1 |
| Altavilla, D; Bagnato, G; Bitto, A; Cinquegrani, M; Irrera, N; Matucci Cerinic, M; Pizzino, G; Roberts, WN; Saitta, A; Sangari, D; Squadrito, F | 1 |
| Altavilla, D; Bagnato, GF; Bagnato, GL; Bitto, A; Irrera, N; Minutoli, L; Pizzino, G; Roberts, WN; Russo, G; Saitta, A; Squadrito, F | 1 |
| Comina, DP; Cortelezzi, A; Cortiana, M; Del Papa, N; Lucchi, T; Maglione, W; Silvestris, I; Vitali, C | 1 |
| Bazzichi, L; Bombardieri, S; Franzoni, F; Ghiadoni, L; Mencaroni, I; Rossi, M | 1 |
| Fertala, J; Huaman, G; Jiménez, SA; Louneva, N | 1 |
1 trial(s) available for simvastatin and Sclerosis, Systemic
| Article | Year |
|---|---|
Simvastatin reduces endothelial activation and damage but is partially ineffective in inducing endothelial repair in systemic sclerosis.
Topics: Adult; Aged; Aged, 80 and over; Case-Control Studies; Endothelial Cells; Female; Flow Cytometry; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Middle Aged; Scleroderma, Systemic; Simvastatin; Stem Cells | 2008 |
6 other study(ies) available for simvastatin and Sclerosis, Systemic
| Article | Year |
|---|---|
Short course of simvastatin has no effect on markers of endothelial activation in normolipidemic patients with systemic sclerosis.
Topics: Biomarkers; Cell Adhesion Molecules; Endothelial Cells; Female; Humans; Lipids; Male; Middle Aged; Scleroderma, Systemic; Simvastatin | 2018 |
Statins Inhibit Cytokines in a Dose-Dependent Response in Patients with Systemic Sclerosis.
Topics: Blood Specimen Collection; Cells, Cultured; Cytokines; Dose-Response Relationship, Drug; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Leukocytes, Mononuclear; Male; Middle Aged; Scleroderma, Systemic; Simvastatin; T-Lymphocytes, Helper-Inducer | 2019 |
Simvastatin attenuates the development of pulmonary and cutaneous fibrosis in a murine model of systemic sclerosis.
Topics: Animals; Biopsy, Needle; Blotting, Western; Disease Models, Animal; Dose-Response Relationship, Drug; Fibrosis; Immunohistochemistry; Mice; Mice, Inbred BALB C; Pulmonary Fibrosis; Random Allocation; Reactive Oxygen Species; Scleroderma, Systemic; Sensitivity and Specificity; Simvastatin; Skin Diseases; Transforming Growth Factor beta; Vascular Endothelial Growth Factor A | 2013 |
Simvastatin prevents vascular complications in the chronic reactive oxygen species murine model of systemic sclerosis.
Topics: Animals; Aorta; Carotid Intima-Media Thickness; Cell Differentiation; Collagen; Disease Models, Animal; Gene Expression Regulation; Humans; Hypochlorous Acid; Kidney; Mice; Myofibroblasts; Platelet Endothelial Cell Adhesion Molecule-1; Reactive Oxygen Species; Scleroderma, Systemic; Simvastatin; Vascular Endothelial Growth Factor Receptor-2 | 2016 |
Increased finger skin vasoreactivity and stimulated vasomotion associated with simvastatin therapy in systemic sclerosis hypercholesterolemic patients.
Topics: Adult; Aged; Anticholesteremic Agents; Female; Fingers; Humans; Hypercholesterolemia; Hyperemia; Microvessels; Middle Aged; Regional Blood Flow; Scleroderma, Systemic; Simvastatin; Skin; Treatment Outcome | 2012 |
Inhibition of systemic sclerosis dermal fibroblast type I collagen production and gene expression by simvastatin.
Topics: Cells, Cultured; Collagen Type I; Fibroblasts; Gene Expression; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Scleroderma, Systemic; Simvastatin; Skin | 2006 |